- Home
- PHD vs IRWD Comparison
PHD vs IRWD Comparison
Compare PHD & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHD
- IRWD
- Stock Information
- Founded
- PHD 2004
- IRWD 1998
- Country
- PHD United States
- IRWD United States
- Employees
- PHD N/A
- IRWD N/A
- Industry
- PHD Investment Managers
- IRWD Biotechnology: Pharmaceutical Preparations
- Sector
- PHD Finance
- IRWD Health Care
- Exchange
- PHD Nasdaq
- IRWD Nasdaq
- Market Cap
- PHD 120.3M
- IRWD 97.4M
- IPO Year
- PHD N/A
- IRWD 2010
- Fundamental
- Price
- PHD $9.82
- IRWD $0.78
- Analyst Decision
- PHD
- IRWD Buy
- Analyst Count
- PHD 0
- IRWD 5
- Target Price
- PHD N/A
- IRWD $4.94
- AVG Volume (30 Days)
- PHD 67.7K
- IRWD 2.7M
- Earning Date
- PHD 01-01-0001
- IRWD 08-07-2025
- Dividend Yield
- PHD 11.43%
- IRWD N/A
- EPS Growth
- PHD N/A
- IRWD N/A
- EPS
- PHD 1.27
- IRWD N/A
- Revenue
- PHD N/A
- IRWD $317,676,000.00
- Revenue This Year
- PHD N/A
- IRWD N/A
- Revenue Next Year
- PHD N/A
- IRWD N/A
- P/E Ratio
- PHD $7.60
- IRWD N/A
- Revenue Growth
- PHD N/A
- IRWD N/A
- 52 Week Low
- PHD $8.30
- IRWD $0.53
- 52 Week High
- PHD $9.81
- IRWD $7.11
- Technical
- Relative Strength Index (RSI)
- PHD 62.38
- IRWD 56.76
- Support Level
- PHD $9.67
- IRWD $0.66
- Resistance Level
- PHD $9.83
- IRWD $0.74
- Average True Range (ATR)
- PHD 0.05
- IRWD 0.08
- MACD
- PHD -0.01
- IRWD 0.02
- Stochastic Oscillator
- PHD 93.75
- IRWD 74.36
About PHD Pioneer Floating Rate Fund Inc.
Pioneer Floating Rate Trust is a diversified, closed-end fund. It invests in the fixed income markets of the United States. The fund basically invests in senior secured floating-rate loans. It benchmarks the performance of its portfolio against the other High Yield Loans Index banks.
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.